ClinicalTrials.gg
RecruitingNCT05582161Updated Mar 19, 2026

Efficacy Biomarkers of DAOIB for Dementia

A Phase 2 interventional study of DAOIB in Dementia, sponsored by Chang Gung Memorial Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Dementia by Chang Gung Memorial Hospital — 9 open to participants now, 10 under way, none of them phase 3. Dementia · Chang Gung Memorial Hospital.

Planned enrollment
9th of 21
123 · median 97
Started
2022
with 2 others
Phase 2
7 of 23
2 open now
Registered
16th of 23
by date

Among the 23 studies in Dementia by Chang Gung Memorial Hospital, this one is the 9th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 2, and was the 16th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

9 of the 23 studies in Dementia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dementia by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.

03

Conditions studied

  • Dementia

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
  • between 10-26
  • CDR 1 or 0.5

Exclusion criteria

Exclusion Criteria:

  • Hachinski Ischemic Score > 4
  • Substance abuse/dependence
  • Parkinson disease, epilepsy, dementia with psychotic features
  • Major depressive disorder
  • Major physical illnesses
  • Severe visual or hearing impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    DAOIB

    Drug: DAOIB

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

    Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)

    Time frame: week 0, 8, 16, 24

Secondary outcomes

  1. Change from baseline in the composite score of a battery of additional cognitive tests at week 24

    The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing)

    Time frame: week 0, 24

  2. Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Time frame: week 8, 16, 24

  3. Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24

    The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)

    Time frame: week 0, 8, 16, 24

  4. Change from baseline of Geriatric Depression Scale

    Assessment of geriatric depressive symptoms

    Time frame: week 0, 8, 16, 24

  5. Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24

    Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24

    Time frame: week 0, 8, 16, 24

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Sep 2026, 47 months after the start.

Of 43 non-industry phase 2 interventional studies under Dementia, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 78. This study's planned 47 months is below that.

Counting every sponsor, half of 84 studies reached it within 38 months; a quarter within 23 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 17, 2022
StartActual
Oct 3, 2022
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05582161
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Oct 3, 2022
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Benzoate

Start the discussion